Cynata Therapeutics Limited
CYYNF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | -$85 | $1,970 | -$230 | $2,546 |
| % Growth | -104.3% | 956.3% | -109% | – |
| Cost of Goods Sold | $0 | $0 | $140 | $140 |
| Gross Profit | -$85 | $1,970 | -$230 | $1,132 |
| % Margin | 100% | 100% | 100% | 44.5% |
| R&D Expenses | $7,681 | $0 | $3,662 | $5,301 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $2,225 | $4,553 | $1,589 | $6,946 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$6,193 |
| Operating Expenses | $9,906 | $4,553 | $5,251 | $6,054 |
| Operating Income | -$9,991 | -$2,583 | -$1,721 | -$3,417 |
| % Margin | 11,755.8% | -131.1% | 748.1% | -134.2% |
| Other Income/Exp. Net | $4,250 | -$1,067 | -$3,482 | -$3,440 |
| Pre-Tax Income | -$5,741 | -$3,650 | -$5,204 | -$6,857 |
| Tax Expense | $0 | $0 | $0 | -$2,316 |
| Net Income | -$5,741 | -$3,650 | -$5,204 | -$4,541 |
| % Margin | 6,755.1% | -185.3% | 2,261.8% | -178.4% |
| EPS | -0.025 | -0.02 | -0.029 | -0.025 |
| % Growth | -28.3% | 31.7% | -14.6% | – |
| EPS Diluted | -0.025 | -0.02 | -0.029 | -0.025 |
| Weighted Avg Shares Out | 225,571 | 184,333 | 179,632 | 179,632 |
| Weighted Avg Shares Out Dil | 225,569 | 184,333 | 179,632 | 179,632 |
| Supplemental Information | – | – | – | – |
| Interest Income | $228 | $0 | $188 | $230 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $146 | $137 | $140 | $140 |
| EBITDA | -$5,815 | -$3,513 | -$5,549 | -$6,946 |
| % Margin | 6,842.2% | -178.3% | 2,411.9% | -272.9% |